DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Clinical trials for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA explained in plain language.
Never miss a new study
Get alerted when new DLBCL - DIFFUSE LARGE B CELL LYMPHOMA trials appear
Sign up with your email to follow new studies for DLBCL - DIFFUSE LARGE B CELL LYMPHOMA, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
Double attack: new combo therapy targets tough lymphoma
Disease control Not yet recruitingThis study tests whether combining two powerful treatments—glofitamab and CAR-T therapy—can help people with a high-risk form of large B-cell lymphoma that has come back or not responded to prior treatment. About 24 participants will receive the combination at a single center. Th…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 17, 2026 03:13 UTC
-
Chemo-Free cocktail aims to tackle aggressive lymphoma in Early-Stage trial
Disease control Not yet recruitingThis study tests a combination of three drugs (glofitamab, polatuzumab vedotin, and zuberitamab) as a chemotherapy-free option for people newly diagnosed with diffuse large B-cell lymphoma. About 40 adults with intermediate-to-high risk disease will receive the treatment to see h…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Li Zhiming • Aim: Disease control
Last updated May 17, 2026 03:12 UTC
-
Promising new cocktail targets tough lymphoma in seniors
Disease control Not yet recruitingThis study tests a new combination of drugs for people aged 65 and older with a fast-growing type of lymphoma called double/triple-hit diffuse large B-cell lymphoma. Participants will receive six cycles of the CL-Pola-R-CHP regimen, which adds two newer targeted drugs to a standa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE2 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 17, 2026 03:11 UTC
-
New hope for aggressive lymphoma: targeted combo trial launches
Disease control Not yet recruitingThis study tests whether a new combination of drugs (C Pola R-CHP+X) works better than the current standard treatment for people with a fast-growing type of lymphoma called double-expressor DLBCL. About 156 adults aged 18 to 75 who have not been treated before will take part. The…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Ruijin Hospital • Aim: Disease control
Last updated May 17, 2026 03:08 UTC
-
New hope for tough lymphoma? Real-World glofitamab study launches
Disease control Not yet recruitingThis study will observe about 20 adults with a type of blood cancer called diffuse large B-cell lymphoma that did not respond to or came back quickly after first treatment. Researchers will track how well the drug glofitamab works when given as part of routine care, either alone …
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated May 17, 2026 02:58 UTC
-
New hope for hard-to-treat lymphoma: experimental drug combo enters phase 3 trial
Disease control Not yet recruitingThis phase 3 trial compares a new drug (SCTB35) plus chemotherapy against a standard drug (rituximab) plus chemotherapy in about 101 adults with diffuse large B-cell lymphoma that has come back or not responded to prior treatment. The goal is to see if the new combination works b…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: PHASE3 • Sponsor: Sinocelltech Ltd. • Aim: Disease control
Last updated May 13, 2026 15:59 UTC
-
New hope for lymphoma patients whose cancer returns after a year
Disease control Not yet recruitingThis study tests two different chemotherapy combinations in 70 adults whose diffuse large B-cell lymphoma has come back more than 12 months after initial treatment. Participants will receive either the modified R-MINE regimen or the R-GemOx regimen for four 21-day cycles. The goa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Phase: NA • Sponsor: The First Affiliated Hospital with Nanjing Medical University • Aim: Disease control
Last updated May 07, 2026 18:40 UTC
-
15-Year Check-In: how safe is this CAR T-Cell therapy?
Knowledge-focused Not yet recruitingThis study follows 18 people who already received GF-CART01, a type of cell therapy for certain blood cancers like lymphoma. Researchers will monitor participants for up to 15 years to see if any serious side effects occur and how long the modified cells stay in the body. The goa…
Matched conditions: DLBCL - DIFFUSE LARGE B CELL LYMPHOMA
Sponsor: GenomeFrontier Therapeutics TW Co., Ltd. • Aim: Knowledge-focused
Last updated May 15, 2026 11:57 UTC